Immature and mature species of the human Prostacyclin Receptor are ubiquitinated and targeted to the 26S proteasomal or lysosomal degradation pathways, respectively
Tóm tắt
The human prostacyclin receptor (hIP) undergoes agonist-induced phosphorylation, desensitisation and internalisation and may be recycled to the plasma membrane or targeted for degradation by, as yet, unknown mechanism(s). Herein it was sought to investigate the turnover of the hIP under basal conditions and in response to cicaprost stimulation. It was established that the hIP is subject to low-level basal degradation but, following agonist stimulation, degradation is substantially enhanced. Inhibition of the lysosomal pathway prevented basal and agonist-induced degradation of the mature species of the hIP (46-66 kDa). Conversely, inhibition of the proteasomal pathway had no effect on levels of the mature hIP but led to time-dependent accumulation of four newly synthesised immature species (38-44 kDa). It was established that both the mature and immature species of the hIP may be polyubiquitinated and this modification may be required for lysosomal sorting of the mature, internalised receptors and for degradation of the immature receptors by the 26S proteasomes through the ER-associated degradation (ERAD) process, respectively. Moreover, these data substantially advance knowledge of the factors regulating processing and maturation of the hIP, a complex receptor subject to multiple post-translational modifications including N-glycosylation, phosphorylation, isoprenylation, palmitoylation, in addition to polyubiquitination, as determined herein. These findings indicate that the hIP is post-translationally modified by ubiquitination, which targets the immature species to the 26S proteasomal degradation pathway and the mature species to the lysosomal degradation pathway.
Tài liệu tham khảo
Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193–1226.
Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678–682.
Zucker TP, Bonisch D, Hasse A, Grosser T, Weber AA, Schror K: Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol 1998, 345:213–220.
Kothapalli D, Stewart SA, Smyth EM, Azonobi I, Pure E, Assoian RK: Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol 2003, 64:249–258.
Fetalvero KM, Martin KA, Hwa J: Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat 2007, 82:109–118.
Belvisi MG, Saunders M, Yacoub M, Mitchell JA: Expression of cyclo-oxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth. Br J Pharmacol 1998, 125:1102–1108.
Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW: Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000, 102:3130–3136.
Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539–541.
Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA: COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306:1954–1957.
Patrignani P, Di Febbo C, Tacconelli S, Douville K, Guglielmi MD, Horvath RJ, Ding M, Sierra K, Stitham J, Gleim S, Baccante G, Moretta V, Di Francesco L, Capone ML, Porreca E, Hwa J: Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenet Genomics 2008, 18:611–620.
Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL: A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 1994, 47:151–168.
Hebert RL, O'Connor T, Neville C, Burns KD, Laneuville O, Peterson LN: Prostanoid signaling, localization, and expression of IP receptors in rat thick ascending limb cells. Am J Physiol 1998, 275:F904–914.
Lawler OA, Miggin SM, Kinsella BT: Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-, to G(i)-, and to G(q)-coupled effector signaling. J Biol Chem 2001, 276:33596–33607.
Miggin SM, Kinsella BT: Investigation of the mechanisms of G protein: effector coupling by the human and mouse prostacyclin receptors. Identification of critical species-dependent differences. J Biol Chem 2002, 277:27053–27064.
Schubert R, Serebryakov VN, Mewes H, Hopp HH: Iloprost dilates rat small arteries: role of K(ATP)- and K(Ca)-channel activation by cAMP-dependent protein kinase. Am J Physiol 1997, 272:H1147–1156.
Siegel G, Carl A, Adler A, Stock G: Effect of the prostacyclin analogue iloprost on K+ permeability in the smooth muscle cells of the canine carotid artery. Eicosanoids 1989, 2:213–222.
Smyth EM, Nestor PV, FitzGerald GA: Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 1996, 271:33698–33704.
Zhang Z, Austin SC, Smyth EM: Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction. Mol Pharmacol 2001, 60:480–487.
Miggin SM, Lawler OA, Kinsella BT: Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem 2003, 278:6947–6958.
Miggin SM, Lawler OA, Kinsella BT: Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem 2002, 269:1714–1725.
Drake MT, Shenoy SK, Lefkowitz RJ: Trafficking of G protein-coupled receptors. Circ Res 2006, 99:570–582.
Marchese A, Chen C, Kim YM, Benovic JL: The ins and outs of G protein-coupled receptor trafficking. Trends Biochem Sci 2003, 28:369–376.
Giovanazzi S, Accomazzo MR, Letari O, Oliva D, Nicosia S: Internalization and down-regulation of the prostacyclin receptor in human platelets. Biochem J 1997,325(Pt 1):71–77.
O'Keeffe MB, Reid HM, Kinsella BT: Agonist-dependent internalization and trafficking of the human prostacyclin receptor: A direct role for Rab5a GTPase. Biochim Biophys Acta 2008, 1783:1914–1928.
Smyth EM, Austin SC, Reilly MP, FitzGerald GA: Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 2000, 275:32037–32045.
Smyth EM, Li WH, FitzGerald GA: Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c. J Biol Chem 1998, 273:23258–23266.
Wikstrom K, Reid HM, Hill M, English KA, O'Keeffe MB, Kimbembe CC, Kinsella BT: Recycling of the human prostacyclin receptor is regulated through a direct interaction with Rab11a GTPase. Cell Signal 2008,20(12):2332–46. Epub 2008 Sep 7
Wilson SJ, Smyth EM: Internalization and recycling of the human prostacyclin receptor is modulated through its isoprenylation-dependent interaction with the delta subunit of cGMP phosphodiesterase 6. J Biol Chem 2006, 281:11780–11786.
Ciechanover A: Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005, 6:79–87.
Cuervo AM, Dice JF: Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med 1998, 76:6–12.
Pickart CM, Cohen RE: Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 2004, 5:177–187.
Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373–428.
Martin NP, Lefkowitz RJ, Shenoy SK: Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. J Biol Chem 2003, 278:45954–45959.
Jacob C, Cottrell GS, Gehringer D, Schmidlin F, Grady EF, Bunnett NW: c-Cbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2. J Biol Chem 2005, 280:16076–16087.
Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ: Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001, 294:1307–1313.
Chaturvedi K, Bandari P, Chinen N, Howells RD: Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors. J Biol Chem 2001, 276:12345–12355.
Marchese A, Benovic JL: Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 2001, 276:45509–45512.
Marchese A, Paing MM, Temple BR, Trejo J: G Protein-Coupled Receptor Sorting to Endosomes and Lysosomes. Annu Rev Pharmacol Toxicol 2008, 48:601–29.
Shenoy SK: Seven-transmembrane receptors and ubiquitination. Circ Res 2007, 100:1142–1154.
Meusser B, Hirsch C, Jarosch E, Sommer T: ERAD: the long road to destruction. Nat Cell Biol 2005, 7:766–772.
Petaja-Repo UE, Hogue M, Laperriere A, Bhalla S, Walker P, Bouvier M: Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. J Biol Chem 2001, 276:4416–4423.
Lawler OA, Miggin SM, Kinsella BT: The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor. Br J Pharmacol 2001, 132:1639–1649.
O'Meara SJ, Kinsella BT: The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor. Biochem J 2005, 386:177–189.
Taveras AG, Kirschmeier P, Baum CM: Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations. Curr Top Med Chem 2003, 3:1103–1114.
Caponigro F: Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs 2002, 13:891–897.
Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739–758.
Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S: Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem (Tokyo) 1996, 119:572–576.
Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8:397–403.
Romisch K: Endoplasmic reticulum-associated degradation. Annu Rev Cell Dev Biol 2005, 21:435–456.
Hanyaloglu AC, von Zastrow M: Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol 2008, 48:537–568.
Marchese A, Paing MM, Temple BR, Trejo J: G protein-coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol 2008, 48:601–629.
Amerik AY, Nowak J, Swaminathan S, Hochstrasser M: The Doa4 deubiquitinating enzyme is functionally linked to the vacuolar protein-sorting and endocytic pathways. Mol Biol Cell 2000, 11:3365–3380.
Rapoport TA: Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 2007, 450:663–669.
Kopito RR: Biosynthesis and degradation of CFTR. Physiol Rev 1999, 79:S167–173.
Petaja-Repo UE, Hogue M, Laperriere A, Walker P, Bouvier M: Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor. J Biol Chem 2000, 275:13727–13736.
Illing ME, Rajan RS, Bence NF, Kopito RR: A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J Biol Chem 2002, 277:34150–34160.
Saliba RS, Munro PM, Luthert PJ, Cheetham ME: The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J Cell Sci 2002, 115:2907–2918.
Cook LB, Zhu CC, Hinkle PM: Thyrotropin-releasing hormone receptor processing: role of ubiquitination and proteasomal degradation. Mol Endocrinol 2003, 17:1777–1791.
Huang Y, Niwa J, Sobue G, Breitwieser GE: Calcium-sensing receptor ubiquitination and degradation mediated by the E3 ubiquitin ligase dorfin. J Biol Chem 2006, 281:11610–11617.
Dobson CM: Getting out of shape. Nature 2002, 418:729–730.
Marchese A, Raiborg C, Santini F, Keen JH, Stenmark H, Benovic JL: The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell 2003, 5:709–722.
Cottrell GS, Padilla B, Pikios S, Roosterman D, Steinhoff M, Gehringer D, Grady EF, Bunnett NW: Ubiquitin-dependent down-regulation of the neurokinin-1 receptor. J Biol Chem 2006, 281:27773–27783.
Norel X: Prostanoid receptors in the human vascular wall. ScientificWorldJournal 2007, 7:1359–1374.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248–254.
Liang W, Fishman PH: Resistance of the human beta1-adrenergic receptor to agonist-induced ubiquitination: a mechanism for impaired receptor degradation. J Biol Chem 2004, 279:46882–46889.
Gorman CM, Gies D, McCray G: Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng Tech 2 1990, 3–10.
Hayes JS, Lawler OA, Walsh MT, Kinsella BT: The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. J Biol Chem 1999, 274:23707–23718.
Kinsella BT, O'Mahony DJ, Fitzgerald GA: The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 1997, 281:957–964.